Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Senti Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Senti Biosciences, Inc.

SNTI

Senti Biosciences, Inc.

About Senti Biosciences, Inc.

Senti Biosciences is a biotech company developing cell and gene therapies using proprietary gene circuit platform technologies. Its focus is on engineering smarter, programmable therapies for cancer and other diseases, primarily through off-the-shelf CAR-NK cell products targeting hematologic and solid tumors. The company emphasizes precision, safety, and control in immunotherapy, leveraging synthetic biology, strategic collaborations, and advanced manufacturing to address unmet medical needs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Senti Biosciences, Inc.

1
1
Senti Biosciences, Inc. Senti Biosciences Reports $4.2 Million Net Loss and First Revenue Generation in Q1 2026

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Senti Biosciences, Inc. Senti Biosciences Reports $61.4 Million Net Loss and Faces Funding Challenges in 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Senti Biosciences, Inc. Senti Biosciences Reports $18.1 Million Net Loss in Q3 2025, Faces Liquidity Challenges

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Senti Biosciences, Inc. Senti Biosciences Reports $14.7 Million Net Loss in Q2 2025, Seeks Additional Funding

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Senti Biosciences, Inc. Senti Biosciences Reports $52.8 Million Net Loss for 2024, Initiates Phase 1 Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Senti Biosciences, Inc. Senti Biosciences Reports Significant Financial Challenges, No Revenue in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments